Tags

Type your tag names separated by a space and hit enter

Tardive Syndromes.
Continuum (Minneap Minn) 2019; 25(4):1081-1098C

Abstract

PURPOSE OF REVIEW

This article reviews the history, nosology, clinical features, epidemiology, and treatment of tardive syndromes.

RECENT FINDINGS

The major advance in the field of tardive syndromes has been the development and US Food and Drug Administration (FDA) approval of two vesicular monoamine transporter type 2 inhibitors, valbenazine and deutetrabenazine, for treating tardive syndromes. These medications are derivatives of tetrabenazine and reduce dyskinetic movements by reducing dopamine stimulation. Treatment is not curative, and the medications reduce, or "mask," symptoms but presumably without adding to the long-term risk of increased involuntary movements believed to accrue from suppressive treatment with dopamine receptor-blocking drugs. A confounding advance has been the accumulation of data finding that second-generation antipsychotics, also known as atypical antipsychotics, may not be safer than first-generation antipsychotics in causing tardive syndromes. The public health risk of tardive syndromes may actually have increased as some second-generation antipsychotics, widely promoted to both doctors and patients, are increasingly used as antidepressants.

SUMMARY

Tardive syndromes remain a public health risk. Second-generation antipsychotics have not been proven to have less risk than first-generation drugs in causing tardive syndromes and are nevertheless being used more widely to treat depression, bipolar disease, and insomnia. Symptomatic treatment for tardive syndromes is available, although expensive.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31356294

Citation

Friedman, Joseph H.. "Tardive Syndromes." Continuum (Minneapolis, Minn.), vol. 25, no. 4, 2019, pp. 1081-1098.
Friedman JH. Tardive Syndromes. Continuum (Minneap Minn). 2019;25(4):1081-1098.
Friedman, J. H. (2019). Tardive Syndromes. Continuum (Minneapolis, Minn.), 25(4), pp. 1081-1098. doi:10.1212/CON.0000000000000754.
Friedman JH. Tardive Syndromes. Continuum (Minneap Minn). 2019;25(4):1081-1098. PubMed PMID: 31356294.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tardive Syndromes. A1 - Friedman,Joseph H, PY - 2019/7/30/entrez PY - 2019/7/30/pubmed PY - 2019/7/30/medline SP - 1081 EP - 1098 JF - Continuum (Minneapolis, Minn.) JO - Continuum (Minneap Minn) VL - 25 IS - 4 N2 - PURPOSE OF REVIEW: This article reviews the history, nosology, clinical features, epidemiology, and treatment of tardive syndromes. RECENT FINDINGS: The major advance in the field of tardive syndromes has been the development and US Food and Drug Administration (FDA) approval of two vesicular monoamine transporter type 2 inhibitors, valbenazine and deutetrabenazine, for treating tardive syndromes. These medications are derivatives of tetrabenazine and reduce dyskinetic movements by reducing dopamine stimulation. Treatment is not curative, and the medications reduce, or "mask," symptoms but presumably without adding to the long-term risk of increased involuntary movements believed to accrue from suppressive treatment with dopamine receptor-blocking drugs. A confounding advance has been the accumulation of data finding that second-generation antipsychotics, also known as atypical antipsychotics, may not be safer than first-generation antipsychotics in causing tardive syndromes. The public health risk of tardive syndromes may actually have increased as some second-generation antipsychotics, widely promoted to both doctors and patients, are increasingly used as antidepressants. SUMMARY: Tardive syndromes remain a public health risk. Second-generation antipsychotics have not been proven to have less risk than first-generation drugs in causing tardive syndromes and are nevertheless being used more widely to treat depression, bipolar disease, and insomnia. Symptomatic treatment for tardive syndromes is available, although expensive. SN - 1538-6899 UR - https://www.unboundmedicine.com/medline/citation/31356294/Tardive_Syndromes L2 - http://dx.doi.org/10.1212/CON.0000000000000754 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows